Magnetic resonance imaging (MRI) is the current standard neuroimaging modality for patients with high-grade gliomas (HGG). A valuable addition to the morphologic information obtained from MRI is magnetic resonance spectroscopy (MRS), which provides information regarding the metabolic status of the brain and tumor. In the clinical setting, MRS can be obtained during the same session as the MRI examination, therefore providing both morphological and metabolic imaging with minimal additional time.
INTRODUCTION
Magnetic resonance imaging (MRI) is the current standard neuroimaging modality for patients with high-grade gliomas (HGG) . A valuable addition to the morphologic information obtained from MRI is magnetic resonance spectroscopy (MRS), which provides information regarding the metabolic status of the brain and tumor. In the clinical setting, MRS can be obtained during the same session as the MRI examination, therefore providing both morphological and metabolic imaging with minimal additional time. As the literature regarding the use of MRS for patients with gliomas has increased substantially over the last decade, MRS has become an essential part of the clinical management of patients with HGG. Metabolic data obtained from MRS provides information that is useful at various stages of HGG management including diagnosis, treatment planning, and evaluation of response to therapy. This chapter outlines the basic principles of MRS, how various metabolites are altered in HGG, and the use of MRS in the multidisciplinary management of patients harboring these tumors.
BACKGROUND
By using the same basic principles as in MRI, MRS techniques provide metabolic assessments by quantifying the levels of important intracellular compounds. In order to acquire 1H (proton) MR spectra of these compounds, water resonance is suppressed and the area excited by radiofrequency pulse is limited to within the skull to prevent signal contamination from subcutaneous lipids. Spectra from regions of interest (ROI) may be obtained as either a single spectrum from each region (i.e., single-voxel MRS) or as a multidimensional array of spectra (i.e., magnetic resonance spectroscopic imaging [MRSI] ) that is also known as chemical shift imaging (CSI) (1). Single-voxel techniques provide a single spectrum from a defined volume of tissue, and lack spatial resolution, whereas excitation and recording of a multidimensional array of spectra from hundreds of smaller contiguous voxels provide significant increase in spatial resolution. MRSI, the most common method for acquiring spectra in multiple voxels, is important for HGG as these tumors are histologically heterogeneous even within the regions appearing uniform on anatomical imaging, and, tumor cells are often present beyond the area depicted on MRI (2,3).
For HGG that constitute the topic of this chapter, metabolites of interest which can be evaluated with MRS include N-acetylaspartate (NAA), choline (Cho), creatine (Cre), lactate N N (Lac) and lipids. Analysis of proton MRS data entailed selection of a population of normal voxels (typically contralateral to the lesion), based on the absence of disease as seen on T2-weighted and contrast-enhanced T1-weighted images. The Cho and NAA levels in all voxels were then normalized using the mean of the corresponding metabolite levels observed in the normal voxels, generating a unitless measure of metabolite concentrations, which could be compared across examinations with minimal errors from differences in coil loading. Alteration in their respective levels constitutes the basis of metabolic imaging of HGG. In addition, there are other metabolites such as glutathione and alanine, which may have increased levels in meningiomas (4,5), and myo-inositol levels are known to be higher in lower grade gliomas (6). NAA, which is localized in viable neurons and absent in other central nervous system (CNS) cells, is important for the regulation of neuronal protein and neurotransmitter synthesis, and myelin production (7, 8) . NAA is decreased in gliomas when compared with normal brain tissue. However, postradiation neuronal dysfunction may also result in decreased NAA levels (9). Cho and its derivatives that form the Cho peak are involved in membrane phospholipid metabolism. Cho levels are elevated in regions of hypercellularity and increased membrane turnover. In HGG, histologic heterogeneity and presence of necrotic areas may result in highly variable levels of Cho within the tumor (10). The Cre peak, which includes phosphocreatine, is indicative of cellular bioenergetic processes, and is usually reduced in HGG (11, 12) . Lac levels, which indicate anaerobic metabolization of glucose, may represent cellular breakdown, and are very low in normal brain tissue. Although nonspecific, increased Lac levels are often seen in HGG (11, 12) .
USE OF MAGNETIC RESONANCE SPECTROSCOPY IN THE CLINICAL SETTING
Metabolic data obtained from MRS provides information that is useful at various stages of HGG management including diagnosis, treatment planning, and evaluation of response to therapy.
Preoperative Evaluation and Surgical Planning
Over the past 15 yr, MRS techniques have been used to help differentiate tumor from normal brain in patients suspected of harboring HGG, to predict histological grade, and for surgical planning. Increased Cho levels and decreased NAA levels when compared with normal brain are general characteristics of gliomas. However, these alterations may also be observed in conditions where membrane turnover is increased and mature neuron populations are decreased.
Although histological diagnosis is the undisputable standard for the diagnosis and grading of gliomas, there has been interest in using MRS to correlate metabolite levels with histological grade (13, 14) . In general, further variation from normal metabolite peaks is considered to correlate with histologically higher grades (15) (Fig. 1) . The reports in the literature are controversial, however, and despite some promising reports, the quality of evidence is limited
